StockCIK 1690585
Dianthus Therapeutics, Inc. /DE/ (DNTH): Insider Trades and Fund Holdings
In the past 12 months, Dianthus Therapeutics, Inc. /DE/ insiders reported 0 open-market purchases worth $0 and 3 sales worth $4.81M; 3 of the sales were reported as made under a 10b5-1 trading plan.
0Insider buys, 12 months
$0Bought by insiders, 12 months
$4.81MSold by insiders, 12 months
0Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Sep 18, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Sep 18 | Edward CarrCAO | ▼ SELL10b5-1 | $2.03M |
| Sep 3 | Simrat RandhawaEVP | ▼ SELL10b5-1 | $2.46M |
| Aug 19 | Simon ReadDirector | ▼ SELL10b5-1 | $327K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Edward Carr | CAO | 0 | $0 | 1 | $2.03M |
| Simrat Randhawa | EVP | 0 | $0 | 1 | $2.46M |
| Simon Read | Director | 0 | $0 | 1 | $327K |
ADVERTISEMENT
320 × 100 ad slot
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →